Helen Willcockson

Dr. Helen Willcockson

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2022 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
RLRichard F. Loeser
Richard F. Loeser
LALiubov Arbeeva
Liubov Arbeeva
KKKathryn Kelley
Kathryn Kelley
AFAnthony A. Fodor
Anthony A. Fodor
SSShan Sun
Shan Sun
ANAmanda E. Nelson
Amanda E. Nelson

1 June 2017 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
HWHelen Willcockson
Helen Willcockson
JTJ.D. Temple
J.D. Temple
LTL. Tagliafierro
L. Tagliafierro
HWH. Willcockson
H. Willcockson
AEAlessandra Esposito
Alessandra Esposito
ASA. Spagnoli
A. Spagnoli

1 September 2018 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
HWHelen Willcockson
Helen Willcockson
JJJ.M. Jordan
J.M. Jordan
XSX.A. Shi
X.A. Shi
JRJ.B. Renner
J.B. Renner
TSTodd A Schwartz
Todd A Schwartz
ASA. Spagnoli
A. Spagnoli

28 November 2014 in Current Osteoporosis Reports
Verified
Journal Article
Closed access
PDF file
HWHelen Willcockson
Helen Willcockson
TLTieshi Li
Tieshi Li
LTLidia Tagliafierro
Lidia Tagliafierro
JTJoseph D. Temple
Joseph D. Temple
HWHelen H. Willcockson
Helen H. Willcockson
ASAnna Spagnoli
Anna Spagnoli

6 January 2021 in Osteoarthritis and Cartilage Open
Verified
Journal Article
Open access
HWHelen Willcockson
Helen Willcockson
HOHuseyin Ozkan
Huseyin Ozkan
SCSusan Chubinskaya
Susan Chubinskaya
RLRichard F. Loeser
Richard F. Loeser
HWHelen Willcockson
Helen Willcockson
In previous studies, we determined an association between increased serum and articular cartilage levels of CCL2 with osteoarthritis (OA) progression, cartilage damage and increased MMP13 in cartilage. Here we analyzed CCL2 downstream signaling mediators that lead to gene expression of cartilage catabolic markers, in healthy and OA human articular chondrocytes. Human articular chondrocytes obtained from healthy or OA subjects were treated with or without recombinant human CCL2; cell lysates or mRNA were collected for immunoblotting or qRT-PCR. For pathway analysis, chondrocytes were pre-incubated with an inhibitor of CCR2 (the unique CCL2 receptor), ERK inhibitor or p38 inhibitor prior to CCL2 treatment. CCL2 treatment of both healthy and OA chondrocytes activated ERK and p38 via CCR2. In healthy chondrocytes, short (6h) and prolonged (24–72h) CCL2 treatments led to Ccr2, Mmp-1, Mmp-3, Mmp-13 and Timp1 upregulation. In OA chondrocytes, CCL2 induced expression of Ccr2, Mmp-1 and Mmp-3, but not Mmp1 and Timp1, and only following longer treatments (72h). In both healthy and OA chondrocytes, the CCL2-mediated upregulation of Ccr2 and cartilage catabolic markers was mediated by ERK and p38 signaling. The triggering of the CCL2/CCR2 axis in articular chondrocytes activates specific MAPK pathways leading to gene expression of cartilage degrading enzymes. However, some differences in the response to CCL2 stimulation are detected in healthy vs OA chondrocytes with respect to the number of activated genes and to the time of exposure to CCL2, suggesting that CCL2 action in articular cartilage may be dependent on OA stage and severity.

6 September 2022 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
HWH. Willcockson
H. Willcockson
HOH. Ozkan
H. Ozkan
LALiubov Arbeeva
Liubov Arbeeva
EME. Mucahit
E. Mucahit
LML. Musawwir
L. Musawwir
HWHelen Willcockson
Helen Willcockson